Life Sciences
Top stories summarized by our editors
10/18/2018

Nordson has paid an undisclosed amount for Ireland-based medtech company Clada Medical Devices, which makes balloons and balloon catheters. Nordson will integrate Clada into its MEDICAL product line in the Advanced Technology Systems segment.

10/18/2018

A round of Series C financing has brought in $20 million for Los Altos, Calif.-based Gauss Surgical, which makes the Triton surgical blood loss monitoring platform.
The company will use the proceeds to continue adoption of its system and create artificial intelligence-driven applications for use in operating rooms.

Full Story:
MassDevice (Boston)
10/18/2018

Researchers at Purdue University have developed paper-based electronic devices that can eventually be used to develop health monitoring and therapeutic medical devices. The flexible, breathable devices, called "smart stickers" by the scientists, are intended to be wirelessly powered and repel oils and water, as the cellulose they are made of is infused with hydrophobic and hydrophilic molecules.

Full Story:
MedGadget
More Summaries:
Purdue University
10/18/2018

GE Healthcare has announced the US launch of its Invenia 2.0 ABUS or automated breast ultrasound system, which is cleared by the FDA for use as a supplemental ultrasound breast screening technology for cancer detection in dense breast tissue. The system comes with the cSound Imageformer software-based graphics processor for data collection and the Reverse Curve transducer for better positioning and scanning coverage.

More Summaries:
GE Healthcare, FDA
10/18/2018

The Easy Trip XR has been launched by Imalin Medical for use in positioning patients' arms over their heads during CT scans. The radiolucent device, made of polypropylene, can help avoid patient movement and provide improved image quality during chest-abdomen-pelvis CT scans.

10/18/2018

The FDA said Wednesday in the Department of Health and Human Services Fall 2018 Unified Agenda of Federal Regulatory and Deregulatory Actions that it will not finalize a 2016 draft guidance that would have required electronic submissions of labeling and package inserts for class II and III home-use devices. The submission would have been used to build an FDA-administered public database of labeling and instructions for such devices.

10/18/2018

European regulators have granted CE-IVD marking to Thermo Fisher Scientific's Oncomine Dx Target Test, a next-generation sequencing-based test that spots 46 cancer-driver gene variants tied to investigational and approved targeted therapies for solid tumors. The test is also validated for use as a companion diagnostic for ALK, ROS1 and other approved non-small cell lung cancer therapies.

10/18/2018

Since Microsoft co-founder Paul Allen donated $100 million in seed money to launch the Allen Institute for Brain Science in 2003, the research organization has grown to almost 500 employees who have cataloged gene expression activity in mouse and human brains, and researchers are now studying how the brain creates consciousness. Allen, who died Monday, continued to fund the institute and encouraged scientists to "think big," says neuroscientist Christof Koch, chief scientist and president of the institute.

Full Story:
National Public Radio
10/18/2018

Taiho Pharmaceutical's venture investment unit has expanded its investment pool to $300 million and is seeking drug discovery opportunities worldwide, primarily in the oncology field. The unit's portfolio includes Arcus Biosciences, Harpoon Therapeutics, Oric Pharmaceuticals, Pact Pharma, Quentis Therapeutics and Storm Therapeutics.

Full Story:
MedCity News
More Summaries:
Taiho Pharmaceutical
10/18/2018

The FDA's Oncology Center of Excellence released two lists of molecular targets for pediatric oncology drugs and biologics, fulfilling a commitment of the FDA Reauthorization Act of 2017. One list contains molecular targets likely involved in pediatric cancer growth or progression, and the other lists targets of drugs being developed that would receive automatic exemption from certain pediatric cancer study requirements.

Full Story:
Regulatory Focus